Sandra X. Franco

Physiatry | Psychology
3200 Long Beach Blvd
Long Beach, CA 90807

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications

An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.

Journal: The oncologist
Published: May 24, 2013

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.

Journal: Breast cancer research and treatment
Published: February 21, 2013

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

Journal: Breast cancer research and treatment
Published: December 07, 2011
Showing 1-3 of 3

Last Updated: 09/26/2026